You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
21. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY et al.<br />
Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with<br />
stage III and stage IV ovarian cancer. N Engl J Med 1996: 334 (1): 1-6<br />
22. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S et al.<br />
Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34-43<br />
23. Nicoletto MO, Tumolo S, Talamini R, et al.: Surgical second look in ovarian cancer: a<br />
randomized study in patients with laparoscopic complete remission--a Northeastern<br />
Oncology Cooperative Group-Ovarian Cancer Cooperative Group Study. J Clin Oncol<br />
1997; 15 (3): 994-9.<br />
24. Dowdy SC, Constaninou CL, Hartman LC, Keeney GL, Suman VJ, Hillman DW, et al.<br />
Long term follow-up of women with ovarian cancer after positive second-look laparotomy.<br />
Gynecol Oncol 2003;91:563-98.<br />
25. Janicke F, Holscher M, Kuhn W, von Hugo R, Pache L, et al Radical surgical<br />
procedure improves survival time in patients with recurrent ovarian cancer. Cancer<br />
1992;70:2129-36.<br />
26. Tay EH, Grant PT, Gebski V, Hacker NF. Secondary cytoreductive surgery for<br />
recurrent epithelial ovarian cancer. Obstet Gynecol 2002;100:1359-62.<br />
27. Hoskins WJ, Rubin SC, Dulaney E, et al.: Influence of secondary cytoreduction at the<br />
time of second-look laparotomy on the survival of patients with epithelial ovarian<br />
carcinoma. Gynecol Oncol 1989; 34 (3): 365-71.<br />
28. Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S et al. Secondline<br />
platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin<br />
Oncol 1991: 9 (3): 389-93.<br />
29. Markman M, Liu P Y, Wilczynski S, et al. Phase III Randomized Trial of 12 versus 3<br />
Months of maintenance after Paclitaxel in Patients with Advanced Ovarian Cancer<br />
Complete Response to Platinum and Paclitaxel-Based Chemotherapy: A Southwest<br />
Oncology Group and Gynecologic Oncology Group Trial. J Clin Oncol. 2003; (13):2460-<br />
5.<br />
30. Parmar MK,Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, et al.<br />
Placlitaxel plus platinum-based chemotherapy versus conventional platinum-based<br />
chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.<br />
Lancet 2005;361:2099-2106.<br />
31. Pfisterer J, Vergote I, du Bois A, Eisenhauer E; AGO-OVAR; NCIC CTG; EORTC<br />
GCG. Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer.<br />
Int J Gynecol Cancer. 2005 May-Jun;15 Suppl 1:36-41.<br />
32. Pfisterer J, Ledermann JA. Management of platinum-sensitive recurrent ovarian cancer.<br />
Semin Oncol. 2006 Apr;33 (2 Suppl 6):S12-6.<br />
33. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent<br />
epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal<br />
doxorubicin versus topotecan. J Clin Oncol 2001: 19 (14): 3312-22.<br />
95
Change language